GSK, Pfizer head into patent duel in high-stakes RSV vaccine war
A patent battle is underway between GSK and Pfizer in the US, with the former calling for a jury trial over their respective RSV vaccines, both set for widespread launch in the fall.
In a fresh lawsuit, GSK is alleging Pfizer infringed on four patents related to GSK’s Arexvy vaccine, which locked in an FDA OK on May 3 in adults 60 years and over. Pfizer’s Abrysvo was approved on May 31.
A court document filed on Wednesday at the Delaware District Court shows the patent dispute revolves around vaccine composition and how they are prepared. Arexvy is designed to induce a response against RSVpreF3, while Abrysvo targets RSV pre F, according to their respective FDA labels.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.